KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EBT: 2010-2025

Historic EBT for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$35.0 million.

  • Nektar Therapeutics' EBT rose 5.47% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.8 million, marking a year-over-year increase of 32.38%. This contributed to the annual value of -$119.2 million for FY2024, which is 56.84% up from last year.
  • As of Q3 2025, Nektar Therapeutics' EBT stood at -$35.0 million, which was up 11.10% from -$39.4 million recorded in Q2 2025.
  • Nektar Therapeutics' EBT's 5-year high stood at $7.0 million during Q4 2024, with a 5-year trough of -$159.0 million in Q2 2022.
  • Its 3-year average for EBT is -$46.9 million, with a median of -$42.1 million in 2023.
  • In the last 5 years, Nektar Therapeutics' EBT plummeted by 56.73% in 2021 and then soared by 116.56% in 2024.
  • Over the past 5 years, Nektar Therapeutics' EBT (Quarterly) stood at -$146.8 million in 2021, then surged by 56.77% to -$63.5 million in 2022, then spiked by 33.65% to -$42.1 million in 2023, then spiked by 116.56% to $7.0 million in 2024, then grew by 5.47% to -$35.0 million in 2025.
  • Its last three reported values are -$35.0 million in Q3 2025, -$39.4 million for Q2 2025, and -$46.4 million during Q1 2025.